2. Baseline evaluations performed within 2 weeks prior to first drug administration. Note: Baseline Labs will not be redrawn if done already as screening within the 2 weeks prior to drug administration. Note: Imaging within 4 weeks prior to drug administration. 3. Therapeutic agents administered will be as outlined in Section 3.1: • Participants will be planned to receive two doses of treatment (HPV vaccine alone in Arm 2A) before definitive standard of care therapy. • Administration of study agents and indicated evaluations can be done up to 3 days earlier or delayed up to 3 days due to holidays, inclement weather, conflicts, or similar reasons. The timing of subsequent administrations is adjusted to maintain a minimum of 11 days between treatments of similar agents. 43 Abbreviated Title: Combo Immunotx in HPV OPSCC Version Date: 04.25.2023 4. EOT – End of treatment visit: Where feasible, on the day of or within 7 days of the decision to discontinue treatment prematurely before completion of one year of treatment prematurely or one month of neoadjuvant or induction treatment. Note: Does not need to be completed if drug is withheld after these timepoints and such participants will be considered off-treatment. 5. Approximately 28 days (+/- 7 days) after last treatment. If subjects are not willing to come to NIH for FU visit, they will be contacted by phone to assess adverse events and for such participants no labs will be needed at FU. 6. Participants who have completed neoadjuvant or induction immunotherapy on the phase II portion of the protocol will be followed by phone or email for recurrence, adverse events and survival starting 2 months (+/- 2 weeks) after safety visit and then annually (+/- 1 month) until the patient is 5 years out from surgery or completion of chemoradiotherapy. 7.